Luminex Launches New Instrument

The latest instrument in the company's line of microsphere-based multiplexed detection instruments based on proprietary xMAP technology has been launched by Luminex Corp. (Austin, TX, USA; www.luminexcorp.com).

The Luminex 200 is designed to meet the multiplexed testing needs of the clinical and research laboratory professional. The instrument incorporates features that further enhance ease of use for end-users and is designed around the same xMAP technology as the Luminex 100, enabling customers who upgrade to this system to continue to use applications validated on earlier systems. The addition of Luminex 200 further solidifies the leadership of Luminex in both nucleic acid- and protein-based multiplexing technology.

"All of us at Luminex are pleased to deliver this exciting new instrument platform to the market,” said Patrick J. Balthrop, CEO of Luminex. "With over 3,000 Luminex instruments sold to date, we have established a clear leadership position in bead-based multiplexing. The newly designed Luminex 200 brings reliability and ease-of-use to even higher levels. Our partners have all expressed excitement about launching this new product to complement their ever-growing application needs.”

The xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate, and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics, and biomedical research, including the genomics and proteomics research markets. The xMAP technology is sold worldwide and is in use in leading research laboratories as well as major diagnostic, pharmaceutical, and biotechnology companies.




Related Links:
Luminex